



ASX Announcement
13 December 2023

Release of securities from escrow

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') advises that in accordance with ASX Listing Rule 3.10A, 6,000,000 fully paid ordinary shares will be released from escrow on 20 December 2023.

These shares were issued on 8 December 2022 in consideration for the acquisition of a 100% interest in a portfolio of matched patient datasets of head and neck pathology, as well as long-term follow up details for patients, histopathological images and annotated data of corresponding confocal and clinical and histopathological images from Professor Camile Farah.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com